This manifesto sets out the views of the ABPI’s members of how to best capitalise on the UK’s life science industry and improve the health of UK patients following the 2019 General Election. We focus on three main themes:
Pharmaceutical companies are doing everything in their power to avoid disruption to the supply of medicines in all Brexit scenarios. This includes increasing stocks of medicine in the UK, changing supply routes, transferring medicine licenses and duplicating testing in the EU.
The objectives of our work are to ensure that patients and public health are central to Brexit negotiations, and that UK Life Sciences is in as strong a position as possible as the UK establishes a new relationship with Europe.
This is the science of developing new tools, standards and approaches to evaluate the efficacy, safety, quality and performance of medical products in order to assess benefit-risk and facilitate a sound and transparent regulatory decision-making.
Drug safety (also known as pharmacovigilance), is the science of detection, assessment, understanding and prevention of side effects which allows us to understand more about the risks and benefits of a medicine.
The UK has a long-standing reputation for world-leading research into life sciences and medicine. Recent development in basic science means we understand diseases better than ever before.
MMIP represents the voice of medicines manufacturers in the UK. It was established jointly by the Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class advanced centre for medicines manufacturing.
To find out more about the career opportunities within each company and to apply for jobs you will need to contact the recruiting companies directly.
The pharmaceutical industry needs a continuous supply of specialists to meet the demands of an evolving, technology-based world. Establishing a skills pipeline remains crucial, even more so following the UK’s decision to exit the EU.
The report, written by Life Science’s Champion Professor Sir John Bell, provides recommendations to government on the long term success of the life sciences sector. It was written in collaboration with industry, academia, charity, and research organisations.
The Office for Life Sciences has today published its annual Life Science Competitiveness Indicators, which highlight the importance of the Industry to the UK economy.